PHASE-II STUDY OF ORAL VP-16-213 IN SMALL-CELL LUNG-CANCER

被引：0
|
作者：
MATSUI, Y
OSHIMA, S
KADO, M
NAKAYAMA, M
SHIMOKATA, K
SAKAI, S
ITO, F
CHIKATA, E
HARA, K
KANDA, T
SHIMA, K
TAKENAKA, S
HOKAMA, S
GENGA, K
机构：
[1] NAGOYA 1ST RED CROSS HOSP,DEPT INTERNAL MED,NAGOYA,JAPAN
[2] NATL TONEYAMA HOSP,DEPT INTERNAL MED,TOYONAKA,JAPAN
[3] UNIV RYUKYUS,SCH MED,DEPT CENT CLIN LAB,NAHA,OKINAWA 903,JAPAN
[4] KUMAMOTO MUNICIPAL HOSP,DEPT INTERNAL MED,KUMAMOTO,JAPAN
[5] KYOTO 1ST RED CROSS HOSP,DEPT RESP DIS,KYOTO,JAPAN
[6] NATL OKINAWA HOSP,DEPT SURG,OKINAWA,JAPAN
[7] NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 464,JAPAN
[8] NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 2,NAGASAKI 852,JAPAN
来源：
CANCER | 1987年 / 60卷 / 12期
关键词：
D O I：
10.1002/1097-0142(19871215)60:12<2882::AID-CNCR2820601205>3.0.CO;2-A
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2882 / 2885
页数：4
相关论文
共 50 条
  • [1] VP-16-213 - A PHASE-II STUDY OF NON-SMALL CELL LUNG-CANCER (NSCLC)
    ITRI, LM
    GRALLA, RJ
    KELSEN, DP
    CHAPMAN, RA
    GOLBEY, RB
    KAUFMAN, RJ
    YOUNG, CW
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 199 - 199
  • [2] PHASE-II TRIAL OF VP-16-213 IN NON-SMALL-CELL LUNG-CANCER
    ITRI, LM
    GRALLA, RJ
    CHAPMAN, RA
    KELSEN, DP
    CASPER, ES
    GOLBEY, RB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (01): : 45 - 47
  • [3] PHASE-II STUDY INDUCTION CHEMOTHERAPY IN SMALL CELL LUNG-CANCER (CISPLATINUM, CYCLOPHOSFAMIDE, VP-16-213)
    MEINESZ, AF
    POSTMUS, PE
    SLEYFER, DT
    SLUITER, HJ
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1982, 63 : 47 - 47
  • [4] HIGH-DOSE CYCLOPHOSPHAMIDE AND HIGH-DOSE VP-16-213 FOR RECURRENT OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II STUDY
    POSTMUS, PE
    MULDER, NH
    DEVRIESHOSPERS, HG
    MULDER, POM
    MAAS, A
    MEINESZ, AF
    SLEIJFER, DT
    DEVRIES, EGE
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (12): : 1467 - 1470
  • [5] CHEMOTHERAPY WITH CISPLATINUM (CDDP) AND VP-16-213 IN SMALL-CELL LUNG-CANCER (SCLC)
    IYER, PR
    MORAN, EM
    KANESHIRO, CA
    CHEN, JJ
    OTTENHEIMER, EJ
    CLINICAL RESEARCH, 1987, 35 (03): : A524 - A524
  • [6] PHASE-II STUDY OF ORAL VP-16-213 IN HEPATOCELLULAR-CARCINOMA
    CAVALLI, F
    ROZENCWEIG, M
    RENARD, J
    GOLDHIRSCH, A
    HANSEN, HH
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1981, 17 (10): : 1079 - 1082
  • [7] ORAL VP-16-213 IN TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - A PHASE-II STUDY
    PANDURO, J
    HANSEN, M
    HANSEN, HH
    CANCER TREATMENT REPORTS, 1981, 65 (7-8): : 703 - 704
  • [8] A PHASE-II STUDY OF ORAL VP-16-213 IN NON-SEMINOMATOUS TESTICULAR CANCER
    CAVALLI, F
    KLEPP, O
    RENARD, J
    ROHRT, M
    ALBERTO, P
    EUROPEAN JOURNAL OF CANCER, 1981, 17 (02) : 245 - 249
  • [9] PHASE-II STUDY OF VP-16-213 (ETOPOSIDE) IN METASTATIC TRANSITIONAL CELL UROTHELIAL CANCER
    PONDER, BAJ
    OLIVER, RTD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 12 (01) : 64 - 65
  • [10] A PHASE-II STUDY OF ORAL VP-16-213 IN PATIENTS WITH NON-SEMINOMATOUS TESTICULAR CANCER
    CAVALLI, F
    KLEPP, O
    RENARD, J
    HANSEN, HH
    ALBERTO, P
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 137 - 137
12345